Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	ryanodine-sensitive calcium-release channel activity	RYR1 RYR2	2.46e-05	4	41	2	GO:0005219
GeneOntologyMolecularFunction	olfactory receptor activity	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	2.48e-05	431	41	7	GO:0004984
GeneOntologyMolecularFunction	intracellularly ligand-gated monoatomic ion channel activity	RYR1 RYR2 HCN3	4.20e-05	33	41	3	GO:0005217
GeneOntologyMolecularFunction	calcium-induced calcium release activity	RYR1 RYR2	6.14e-05	6	41	2	GO:0048763
GeneOntologyMolecularFunction	ligand-gated monoatomic cation channel activity	ABCC8 RYR1 RYR2 HCN3	1.92e-04	140	41	4	GO:0099094
GeneOntologyMolecularFunction	intracellularly gated calcium channel activity	RYR1 RYR2	6.16e-04	18	41	2	GO:0015278
GeneOntologyMolecularFunction	ligand-gated monoatomic ion channel activity	ABCC8 RYR1 RYR2 HCN3	6.48e-04	193	41	4	GO:0015276
GeneOntologyMolecularFunction	ligand-gated channel activity	ABCC8 RYR1 RYR2 HCN3	6.99e-04	197	41	4	GO:0022834
GeneOntologyMolecularFunction	ligand-gated calcium channel activity	RYR1 RYR2	1.84e-03	31	41	2	GO:0099604
GeneOntologyMolecularFunction	G protein-coupled receptor activity	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	1.96e-03	884	41	7	GO:0004930
GeneOntologyMolecularFunction	metal ion transmembrane transporter activity	SLC25A37 ABCC8 RYR1 RYR2 HCN3	2.52e-03	465	41	5	GO:0046873
GeneOntologyMolecularFunction	voltage-gated monoatomic cation channel activity	ABCC8 RYR1 HCN3	3.73e-03	152	41	3	GO:0022843
GeneOntologyMolecularFunction	gated channel activity	ABCC8 RYR1 RYR2 HCN3	4.78e-03	334	41	4	GO:0022836
GeneOntologyMolecularFunction	monoatomic cation channel activity	ABCC8 RYR1 RYR2 HCN3	5.25e-03	343	41	4	GO:0005261
GeneOntologyMolecularFunction	transmembrane signaling receptor activity	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 ABCC8 OR13A1	5.58e-03	1353	41	8	GO:0004888
GeneOntologyMolecularFunction	voltage-gated monoatomic ion channel activity	ABCC8 RYR1 HCN3	6.16e-03	182	41	3	GO:0005244
GeneOntologyMolecularFunction	voltage-gated channel activity	ABCC8 RYR1 HCN3	6.35e-03	184	41	3	GO:0022832
GeneOntologyMolecularFunction	general transcription initiation factor binding	MTOR TP53	7.65e-03	64	41	2	GO:0140296
GeneOntologyBiologicalProcess	detection of chemical stimulus	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 RYR2 OR13A1	7.51e-06	524	41	8	GO:0009593
GeneOntologyBiologicalProcess	detection of chemical stimulus involved in sensory perception of smell	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	2.05e-05	432	41	7	GO:0050911
GeneOntologyBiologicalProcess	sensory perception of smell	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	3.28e-05	465	41	7	GO:0007608
GeneOntologyBiologicalProcess	glucose 6-phosphate metabolic process	G6PC1 MTOR TP53	3.47e-05	32	41	3	GO:0051156
GeneOntologyBiologicalProcess	detection of chemical stimulus involved in sensory perception	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	4.28e-05	485	41	7	GO:0050907
GeneOntologyBiologicalProcess	detection of stimulus	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 RYR2 OR13A1	7.44e-05	722	41	8	GO:0051606
GeneOntologyBiologicalProcess	regulation of pentose-phosphate shunt	MTOR TP53	8.04e-05	7	41	2	GO:0043456
GeneOntologyBiologicalProcess	sensory perception of chemical stimulus	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	9.12e-05	547	41	7	GO:0007606
GeneOntologyBiologicalProcess	detection of stimulus involved in sensory perception	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	1.34e-04	582	41	7	GO:0050906
GeneOntologyBiologicalProcess	regulation of NADP metabolic process	MTOR TP53	1.72e-04	10	41	2	GO:1902031
GeneOntologyBiologicalProcess	cellular response to caffeine	RYR1 RYR2	2.10e-04	11	41	2	GO:0071313
GeneOntologyBiologicalProcess	intrinsic apoptotic signaling pathway in response to hypoxia	TMBIM6 TP53	2.51e-04	12	41	2	GO:1990144
GeneOntologyBiologicalProcess	regulation of glial cell proliferation	MTOR ABCC8 TP53	2.54e-04	62	41	3	GO:0060251
GeneOntologyBiologicalProcess	cellular response to purine-containing compound	RYR1 RYR2	3.46e-04	14	41	2	GO:0071415
GeneOntologyCellularComponent	endoplasmic reticulum membrane	OR2M5 OR2M3 OR2M7 SGMS1 OR2M2 TMBIM6 PLPP2 G6PC1 MTOR RYR1 RYR2	2.12e-05	1293	40	11	GO:0005789
GeneOntologyCellularComponent	endoplasmic reticulum subcompartment	OR2M5 OR2M3 OR2M7 SGMS1 OR2M2 TMBIM6 PLPP2 G6PC1 MTOR RYR1 RYR2	2.22e-05	1299	40	11	GO:0098827
GeneOntologyCellularComponent	nuclear outer membrane-endoplasmic reticulum membrane network	OR2M5 OR2M3 OR2M7 SGMS1 OR2M2 TMBIM6 PLPP2 G6PC1 MTOR RYR1 RYR2	2.70e-05	1327	40	11	GO:0042175
GeneOntologyCellularComponent	junctional sarcoplasmic reticulum membrane	RYR1 RYR2	1.59e-04	10	40	2	GO:0014701
GeneOntologyCellularComponent	sarcolemma	RRAD ABCC8 RYR1 RYR2	4.68e-04	190	40	4	GO:0042383
GeneOntologyCellularComponent	cation channel complex	ABCC8 RYR1 RYR2 HCN3	1.04e-03	235	40	4	GO:0034703
GeneOntologyCellularComponent	PML body	ATR MTOR TP53	1.75e-03	125	40	3	GO:0016605
GeneOntologyCellularComponent	Z disc	NEB RYR1 RYR2	3.00e-03	151	40	3	GO:0030018
GeneOntologyCellularComponent	sarcoplasmic reticulum membrane	RYR1 RYR2	3.36e-03	45	40	2	GO:0033017
GeneOntologyCellularComponent	smooth endoplasmic reticulum	RYR1 RYR2	3.50e-03	46	40	2	GO:0005790
GeneOntologyCellularComponent	I band	NEB RYR1 RYR2	3.92e-03	166	40	3	GO:0031674
HumanPheno	Yellow nails	ATR FOXC2	1.80e-05	3	13	2	HP:0011367
HumanPheno	Sternocleidomastoid amyotrophy	NEB RYR1	3.60e-05	4	13	2	HP:0012036
MousePheno	skeletal muscle fiber degeneration	ZNF106 PFKM RYR1	8.35e-06	21	27	3	MP:0009412
MousePheno	skeletal muscle degeneration	ZNF106 PFKM RYR1	2.52e-05	30	27	3	MP:0009415
MousePheno	abnormal muscle electrophysiology	ZNF106 NEB RYR1	3.07e-05	32	27	3	MP:0004145
MousePheno	abnormal spleen weight	SPO11 PFKM ATR TP53 RYR1 RYR2	5.32e-05	361	27	6	MP:0004951
MousePheno	kyphosis	ZNF106 NEB ATR TP53 RYR1	6.79e-05	229	27	5	MP:0000160
MousePheno	increased variability of skeletal muscle fiber size	ZNF106 NEB RYR1	7.53e-05	43	27	3	MP:0009403
MousePheno	decreased splenocyte apoptosis	MTOR TP53	9.99e-05	8	27	2	MP:0009341
MousePheno	decreased skeletal muscle mass	ZNF106 MTOR TP53 RYR1	1.09e-04	131	27	4	MP:0004819
MousePheno	increased spleen weight	SPO11 PFKM TP53 RYR1 RYR2	1.11e-04	254	27	5	MP:0004952
MousePheno	muscle degeneration	ZNF106 PFKM RYR1	1.58e-04	55	27	3	MP:0000749
MousePheno	abnormal skeletal muscle mass	ZNF106 MTOR TP53 RYR1	1.80e-04	149	27	4	MP:0004817
MousePheno	abnormal thymus weight	ATR TP53 RYR2	2.04e-04	60	27	3	MP:0004954
MousePheno	abnormal spine curvature	ZNF106 NEB ATR TP53 RYR1	3.16e-04	318	27	5	MP:0004174
MousePheno	abnormal skeletal muscle morphology	ZNF106 PFKM NEB MTOR TP53 RYR1	3.45e-04	508	27	6	MP:0000759
MousePheno	premature aging	SPO11 ATR TP53	3.65e-04	73	27	3	MP:0003786
MousePheno	centrally nucleated skeletal muscle fibers	ZNF106 PFKM RYR1	4.78e-04	80	27	3	MP:0009404
MousePheno	decreased skeletal muscle size	ZNF106 MTOR RYR1	4.96e-04	81	27	3	MP:0010240
MousePheno	abnormal splenocyte apoptosis	MTOR TP53	6.02e-04	19	27	2	MP:0009340
MousePheno	abnormal skeletal muscle fiber morphology	ZNF106 PFKM NEB RYR1	6.86e-04	212	27	4	MP:0003084
MousePheno	decreased skeletal muscle fiber number	ZNF106 RYR1	7.38e-04	21	27	2	MP:0009406
MousePheno	abnormal skeletal muscle size	ZNF106 MTOR RYR1	7.43e-04	93	27	3	MP:0009458
MousePheno	pancytopenia	ATR TP53	8.10e-04	22	27	2	MP:0005152
MousePheno	blepharoptosis	NEB FOXC2	8.10e-04	22	27	2	MP:0001344
MousePheno	decreased skeletal muscle fiber size	ZNF106 NEB RYR1	8.39e-04	97	27	3	MP:0009400
MousePheno	abnormal muscle morphology	ZNF106 PFKM NEB MTOR TP53 RYR1 RYR2 FOXC2	8.51e-04	1106	27	8	MP:0002108
MousePheno	abnormal sarcoplasmic reticulum morphology	RYR1 RYR2	8.86e-04	23	27	2	MP:0004088
MousePheno	increased heart weight	RRAD PFKM ATR TP53 RYR2	9.28e-04	403	27	5	MP:0002833
MousePheno	abnormal muscle fiber morphology	ZNF106 PFKM NEB RYR1 RYR2	9.60e-04	406	27	5	MP:0004087
MousePheno	abnormal soleus morphology	ZNF106 RYR1	9.66e-04	24	27	2	MP:0003081
MousePheno	decreased skeletal muscle weight	MTOR RYR1	9.66e-04	24	27	2	MP:0010239
MousePheno	increased thymus weight	TP53 RYR2	9.66e-04	24	27	2	MP:0004955
MousePheno	decreased liver weight	SGMS1 ATR TP53	9.71e-04	102	27	3	MP:0003402
MousePheno	abnormal liver weight	SGMS1 ATR G6PC1 TP53	9.76e-04	233	27	4	MP:0004847
Domain	P_Acid_Pase_2/haloperoxidase	SGMS1 PLPP2 G6PC1	1.09e-05	20	41	3	IPR000326
Domain	PAP2	SGMS1 PLPP2 G6PC1	1.09e-05	20	41	3	PF01569
Domain	RyR	RYR1 RYR2	1.41e-05	3	41	2	PF02026
Domain	Ryanodine_rcpt	RYR1 RYR2	1.41e-05	3	41	2	IPR003032
Domain	RR_TM4-6	RYR1 RYR2	1.41e-05	3	41	2	PF06459
Domain	Ryanrecept_TM4-6	RYR1 RYR2	1.41e-05	3	41	2	IPR009460
Domain	Ryan_recept	RYR1 RYR2	1.41e-05	3	41	2	IPR013333
Domain	Olfact_rcpt	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	2.10e-05	393	41	7	IPR000725
Domain	FATC	ATR MTOR	4.68e-05	5	41	2	PF02260
Domain	FAT	ATR MTOR	7.01e-05	6	41	2	PF02259
Domain	RIH_assoc	RYR1 RYR2	7.01e-05	6	41	2	PF08454
Domain	RIH_assoc-dom	RYR1 RYR2	7.01e-05	6	41	2	IPR013662
Domain	PIK-rel_kinase_FAT	ATR MTOR	7.01e-05	6	41	2	IPR003151
Domain	FATC_dom	ATR MTOR	7.01e-05	6	41	2	IPR003152
Domain	RYDR_ITPR	RYR1 RYR2	7.01e-05	6	41	2	PF01365
Domain	RIH_dom	RYR1 RYR2	7.01e-05	6	41	2	IPR000699
Domain	Ins145_P3_rcpt	RYR1 RYR2	7.01e-05	6	41	2	IPR014821
Domain	Ryanodine_recept-rel	RYR1 RYR2	7.01e-05	6	41	2	IPR015925
Domain	PIK_FAT	ATR MTOR	7.01e-05	6	41	2	IPR014009
Domain	FAT	ATR MTOR	7.01e-05	6	41	2	PS51189
Domain	FATC	ATR MTOR	7.01e-05	6	41	2	PS51190
Domain	Ins145_P3_rec	RYR1 RYR2	7.01e-05	6	41	2	PF08709
Domain	FATC	ATR MTOR	7.01e-05	6	41	2	SM01343
Domain	-	RYR1 RYR2	7.01e-05	6	41	2	1.25.10.30
Domain	MIR	RYR1 RYR2	2.09e-04	10	41	2	PS50919
Domain	MIR	RYR1 RYR2	2.09e-04	10	41	2	PF02815
Domain	MIR	RYR1 RYR2	2.09e-04	10	41	2	SM00472
Domain	MIR_motif	RYR1 RYR2	2.09e-04	10	41	2	IPR016093
Domain	PI3/4_kinase_CS	ATR MTOR	4.85e-04	15	41	2	IPR018936
Domain	PI3Kc	ATR MTOR	5.53e-04	16	41	2	SM00146
Domain	-	ATR MTOR	5.53e-04	16	41	2	1.10.1070.11
Domain	GPCR_Rhodpsn_7TM	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	5.75e-04	670	41	7	IPR017452
Domain	7tm_1	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	6.12e-04	677	41	7	PF00001
Domain	G_PROTEIN_RECEP_F1_1	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	6.56e-04	685	41	7	PS00237
Domain	G_PROTEIN_RECEP_F1_2	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	6.91e-04	691	41	7	PS50262
Domain	GPCR_Rhodpsn	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	6.97e-04	692	41	7	IPR000276
Domain	-	PLPP2 G6PC1	7.04e-04	18	41	2	1.20.144.10
Domain	PI3_4_KINASE_1	ATR MTOR	7.04e-04	18	41	2	PS00915
Domain	PI3_4_KINASE_2	ATR MTOR	7.04e-04	18	41	2	PS00916
Domain	PI3/4_kinase_cat_dom	ATR MTOR	7.04e-04	18	41	2	IPR000403
Domain	PI3_PI4_kinase	ATR MTOR	7.04e-04	18	41	2	PF00454
Domain	PI3_4_KINASE_3	ATR MTOR	7.04e-04	18	41	2	PS50290
Domain	acidPPc	PLPP2 G6PC1	7.04e-04	18	41	2	SM00014
Domain	Ion_trans_dom	RYR1 RYR2 HCN3	1.99e-03	114	41	3	IPR005821
Domain	Ion_trans	RYR1 RYR2 HCN3	1.99e-03	114	41	3	PF00520
Domain	EF-hand_8	RYR1 RYR2	2.52e-03	34	41	2	PF13833
Pathway	KEGG_OLFACTORY_TRANSDUCTION	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	1.07e-05	389	29	7	M14091
Pathway	REACTOME_OLFACTORY_SIGNALING_PATHWAY	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	1.67e-05	417	29	7	M4072
Pathway	BIOCARTA_PLK3_PATHWAY	ATR TP53	1.14e-04	8	29	2	M22021
Pathway	WP_CALORIC_RESTRICTION_AND_AGING	MTOR TP53	1.14e-04	8	29	2	M39743
Pathway	WP_ATM_SIGNALING_IN_DEVELOPMENT_AND_DISEASE	ATR MTOR TP53	1.19e-04	47	29	3	M39518
Pathway	KEGG_MEDICUS_REFERENCE_ATR_P21_CELL_CYCLE_G2_M	ATR TP53	1.46e-04	9	29	2	M47586
Pathway	KEGG_MEDICUS_REFERENCE_CA2_CAM_VGCC_RYR_SIGNALING_PATHWAY	RYR1 RYR2	2.22e-04	11	29	2	M47958
Pathway	REACTOME_SENSORY_PERCEPTION	OR2M5 OR2M3 OR2M7 OR2M2 OR4K13 OR2G6 OR13A1	2.41e-04	636	29	7	M41834
Pathway	WP_CELLTYPE_DEPENDENT_SELECTIVITY_OF_CCK2R_SIGNALING	RYR1 RYR2	3.14e-04	13	29	2	M39589
Pathway	WP_RIOK1_AND_RIOK2_IN_EGFR_AND_PI3KMEDIATED_TUMORIGENESIS	MTOR TP53	4.22e-04	15	29	2	M48306
Pathway	KEGG_MEDICUS_REFERENCE_P300_P21_CELL_CYCLE_G1_S	ATR TP53	4.22e-04	15	29	2	M47524
Pathway	PID_MYC_ACTIV_PATHWAY	PFKM EIF4A1 TP53	5.57e-04	79	29	3	M66
Pathway	REACTOME_TP53_REGULATES_METABOLIC_GENES	GLS2 MTOR TP53	6.67e-04	84	29	3	M27495
Pathway	BIOCARTA_ATRBRCA_PATHWAY	ATR TP53	6.84e-04	19	29	2	MM1478
Pathway	KEGG_MEDICUS_VARIANT_SCRAPIE_CONFORMATION_PRPSC_TO_MGLUR5_CA2_APOPTOTIC_PATHWAY	RYR1 RYR2	6.84e-04	19	29	2	M47760
Pathway	BIOCARTA_MTOR_PATHWAY	MTOR EIF4A1	7.59e-04	20	29	2	MM1437
Pathway	WP_METABOLIC_EPILEPTIC_DISORDERS	GLS2 PFKM G6PC1	8.42e-04	91	29	3	M48079
Pathway	BIOCARTA_ATRBRCA_PATHWAY	ATR TP53	9.20e-04	22	29	2	M9703
Pathway	BIOCARTA_G2_PATHWAY	ATR TP53	9.20e-04	22	29	2	MM1365
Pathway	BIOCARTA_MTOR_PATHWAY	MTOR EIF4A1	9.20e-04	22	29	2	M16563
Pathway	BIOCARTA_EIF4_PATHWAY	MTOR EIF4A1	1.01e-03	23	29	2	MM1470
Pathway	BIOCARTA_G2_PATHWAY	ATR TP53	1.10e-03	24	29	2	M8560
Pathway	BIOCARTA_CTCF_PATHWAY	MTOR TP53	1.10e-03	24	29	2	M11420
Pathway	BIOCARTA_CTCF_PATHWAY	MTOR TP53	1.10e-03	24	29	2	MM1373
Pathway	BIOCARTA_EIF4_PATHWAY	MTOR EIF4A1	1.10e-03	24	29	2	M4791
Pathway	WP_WARBURG_EFFECT_MODULATED_BY_DEUBIQUITINATING_ENZYMES_AND_THEIR_SUBSTRATES	G6PC1 MTOR	1.29e-03	26	29	2	M48054
Pathway	WP_SPHINGOLIPID_METABOLISM_INTEGRATED_PATHWAY	SGMS1 PLPP2	1.29e-03	26	29	2	M39784
Pathway	KEGG_GALACTOSE_METABOLISM	PFKM G6PC1	1.29e-03	26	29	2	M4377
Pathway	WP_SPHINGOLIPID_METABOLISM_OVERVIEW	SGMS1 PLPP2	1.39e-03	27	29	2	M39863
Pathway	WP_ANDROGEN_RECEPTOR_NETWORK_IN_PROSTATE_CANCER	ATR MTOR TP53	1.46e-03	110	29	3	M48043
Pathway	BIOCARTA_G1_PATHWAY	ATR TP53	1.49e-03	28	29	2	M648
Pathway	PID_BARD1_PATHWAY	ATR TP53	1.60e-03	29	29	2	M258
Pathway	BIOCARTA_G1_PATHWAY	ATR TP53	1.60e-03	29	29	2	MM1364
Pubmed	High-throughput microarray detection of olfactory receptor gene expression in the mouse.	OR2M5 OR2M3 OR2M7 OR2M2	1.66e-12	4	41	4	15377787
Pubmed	Quantitative nuclear proteomics identifies mTOR regulation of DNA damage response.	ATR MTOR TP53	6.08e-09	4	41	3	19955088
Pubmed	Tel2 regulates the stability of PI3K-related protein kinases.	ATR MTOR TP53	1.81e-07	10	41	3	18160036
Pubmed	Depletion of proteasome subunit PSMD1 induces cancer cell death via protein ubiquitination and DNA damage, irrespective of p53 status.	PSMD1 TP53	1.36e-06	2	41	2	38580756
Pubmed	Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo.	MTOR TP53	1.36e-06	2	41	2	26577454
Pubmed	Inhibition of mTOR Signaling Enhances Maturation of Cardiomyocytes Derived From Human-Induced Pluripotent Stem Cells via p53-Induced Quiescence.	MTOR TP53	1.36e-06	2	41	2	31707831
Pubmed	Ryanodine receptor oligomeric interaction: identification of a putative binding region.	RYR1 RYR2	1.36e-06	2	41	2	14722100
Pubmed	Structural and functional interactions within ryanodine receptor.	RYR1 RYR2	1.36e-06	2	41	2	26009179
Pubmed	eIF4A inactivates TORC1 in response to amino acid starvation.	MTOR EIF4A1	1.36e-06	2	41	2	26988032
Pubmed	Ryanodine receptors in human pancreatic beta cells: localization and effects on insulin secretion.	RYR1 RYR2	1.36e-06	2	41	2	15033925
Pubmed	Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.	MTOR TP53	1.36e-06	2	41	2	28464864
Pubmed	Downregulation of GLS2 in glioblastoma cells is related to DNA hypermethylation but not to the p53 status.	GLS2 TP53	1.36e-06	2	41	2	26258493
Pubmed	Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species.	GLS2 TP53	1.36e-06	2	41	2	20351271
Pubmed	The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53.	ATR TP53	1.36e-06	2	41	2	10435622
Pubmed	Hypoxia links ATR and p53 through replication arrest.	ATR TP53	1.36e-06	2	41	2	11865061
Pubmed	The human ΔNp53 isoform triggers metabolic and gene expression changes that activate mTOR and alter mitochondrial function.	MTOR TP53	1.36e-06	2	41	2	23734707
Pubmed	Meiotic recombination provokes functional activation of the p53 regulatory network.	SPO11 TP53	1.36e-06	2	41	2	20522776
Pubmed	Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.	MTOR TP53	1.36e-06	2	41	2	20811722
Pubmed	Lethal multiple pterygium syndrome, large cystic hygroma, and cleft palate: Rare and severe fetal presentations of RYR1- and NEB-related congenital myopathies.	NEB RYR1	1.36e-06	2	41	2	38520674
Pubmed	Crystal structures of wild type and disease mutant forms of the ryanodine receptor SPRY2 domain.	RYR1 RYR2	1.36e-06	2	41	2	25370123
Pubmed	DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.	MTOR TP53	1.36e-06	2	41	2	21212465
Pubmed	The increase of cell-membranous phosphatidylcholines containing polyunsaturated fatty acid residues induces phosphorylation of p53 through activation of ATR.	ATR TP53	1.36e-06	2	41	2	18032786
Pubmed	Skeletal and cardiac ryanodine receptors exhibit different responses to Ca2+ overload and luminal ca2+.	RYR1 RYR2	1.36e-06	2	41	2	17259277
Pubmed	Structure and Function of the Human Ryanodine Receptors and Their Association with Myopathies-Present State, Challenges, and Perspectives.	RYR1 RYR2	1.36e-06	2	41	2	32899693
Pubmed	ATR is required to complete meiotic recombination in mice.	SPO11 ATR	1.36e-06	2	41	2	29977027
Pubmed	Ignition of p53 bomb sensitizes tumor cells to granzyme K-mediated cytolysis.	TP53 GZMK	1.36e-06	2	41	2	19201868
Pubmed	Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function.	GLS2 TP53	1.36e-06	2	41	2	20378837
Pubmed	Isolation and mapping of EVX1, a human homeobox gene homologous to even-skipped, localized at the 5' end of HOX1 locus on chromosome 7.	EVX1 EVX2	1.36e-06	2	41	2	1684419
Pubmed	The coordinate regulation of the p53 and mTOR pathways in cells.	MTOR TP53	1.36e-06	2	41	2	15928081
Pubmed	ATR-p53 restricts homologous recombination in response to replicative stress but does not limit DNA interstrand crosslink repair in lung cancer cells.	ATR TP53	1.36e-06	2	41	2	21857991
Pubmed	Recent advances in understanding the ryanodine receptor calcium release channels and their role in calcium signalling.	RYR1 RYR2	1.36e-06	2	41	2	30542613
Pubmed	Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis.	G6PC1 ABCC8	1.36e-06	2	41	2	15735652
Pubmed	Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target RRAD.	RRAD TP53	1.36e-06	2	41	2	25114038
Pubmed	Ryanodine receptors are expressed and functionally active in mouse spermatogenic cells and their inhibition interferes with spermatogonial differentiation.	RYR1 RYR2	1.36e-06	2	41	2	15280431
Pubmed	Expression of the ryanodine receptor isoforms in immune cells.	RYR1 RYR2	1.36e-06	2	41	2	11673493
Pubmed	B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators.	RYR1 RYR2	1.36e-06	2	41	2	11673462
Pubmed	The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression.	ATR TP53	1.36e-06	2	41	2	18089799
Pubmed	ATR (ataxia telangiectasia mutated- and Rad3-related kinase) is activated by mild hypothermia in mammalian cells and subsequently activates p53.	ATR TP53	1.36e-06	2	41	2	21284603
Pubmed	Thermodynamics of calmodulin binding to cardiac and skeletal muscle ryanodine receptor ion channels.	RYR1 RYR2	1.36e-06	2	41	2	18618700
Pubmed	Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice.	TP53 RYR2	1.36e-06	2	41	2	16785989
Pubmed	The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.	MTOR TP53	1.36e-06	2	41	2	20606252
Pubmed	ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.	ATR TP53	4.06e-06	3	41	2	26563132
Pubmed	Type 1 and type 3 ryanodine receptors are selectively involved in muscarinic antinociception in mice: an antisense study.	RYR1 RYR2	4.06e-06	3	41	2	18403125
Pubmed	Expression profiling reveals transcriptional regulation by Fbxw7/mTOR pathway in radiation-induced mouse thymic lymphomas.	MTOR TP53	4.06e-06	3	41	2	26575021
Pubmed	Suppression of Rad leads to arrhythmogenesis via PKA-mediated phosphorylation of ryanodine receptor activity in the heart.	RRAD RYR2	4.06e-06	3	41	2	25193703
Pubmed	ATP depletion triggers acute myeloid leukemia differentiation through an ATR/Chk1 protein-dependent and p53 protein-independent pathway.	ATR TP53	4.06e-06	3	41	2	22621920
Pubmed	The alkylating carcinogen N-methyl-N'-nitro-N-nitrosoguanidine activates the plasminogen activator inhibitor-1 gene through sequential phosphorylation of p53 by ATM and ATR kinases.	ATR TP53	4.06e-06	3	41	2	15735814
Pubmed	Dopamine D1 receptor signaling system regulates ryanodine receptor expression in ethanol physical dependence.	RYR1 RYR2	4.06e-06	3	41	2	23278119
Pubmed	Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53.	ATR TP53	4.06e-06	3	41	2	19718024
Pubmed	p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.	MTOR TP53	4.06e-06	3	41	2	24469052
Pubmed	Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis.	GLS2 TP53	4.06e-06	3	41	2	26751560
Pubmed	Heterogeneous gene expression and functional activity of ryanodine receptors in resistance and conduit pulmonary as well as mesenteric artery smooth muscle cells.	RYR1 RYR2	4.06e-06	3	41	2	18434746
Pubmed	Key mediators of somatic ATR signaling localize to unpaired chromosomes in spermatocytes.	SPO11 ATR	4.06e-06	3	41	2	26209650
Pubmed	SPRY domains in ryanodine receptors (Ca(2+)-release channels).	RYR1 RYR2	4.06e-06	3	41	2	9204703
Pubmed	DNA synthesis from unbalanced nucleotide pools causes limited DNA damage that triggers ATR-CHK1-dependent p53 activation.	ATR TP53	4.06e-06	3	41	2	18434539
Pubmed	Ryanodine receptors are expressed in epidermal keratinocytes and associated with keratinocyte differentiation and epidermal permeability barrier homeostasis.	RYR1 RYR2	4.06e-06	3	41	2	21881589
Pubmed	Isoform-dependent formation of heteromeric Ca2+ release channels (ryanodine receptors).	RYR1 RYR2	4.06e-06	3	41	2	12213830
Pubmed	Activation of the ATM kinase by ionizing radiation and phosphorylation of p53.	ATR TP53	4.06e-06	3	41	2	9733515
Pubmed	RPA and ATR link transcriptional stress to p53.	ATR TP53	4.06e-06	3	41	2	17616578
Pubmed	mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53.	MTOR TP53	4.06e-06	3	41	2	30337688
Pubmed	Calcineurin upregulates local Ca(2+) signaling through ryanodine receptor-1 in airway smooth muscle cells.	RYR1 RYR2	4.06e-06	3	41	2	25239916
Pubmed	Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2).	RYR1 RYR2	4.06e-06	3	41	2	11159936
Pubmed	Chromosomal localization of murine ryanodine receptor genes RYR1, RYR2, and RYR3 by in situ hybridization.	RYR1 RYR2	4.06e-06	3	41	2	7959768
Pubmed	Regulation of mouse egg activation: presence of ryanodine receptors and effects of microinjected ryanodine and cyclic ADP ribose on uninseminated and inseminated eggs.	RYR1 RYR2	4.06e-06	3	41	2	7635066
Pubmed	Mutant p53 and mTOR/PKM2 regulation in cancer cells.	MTOR TP53	4.06e-06	3	41	2	27385486
Pubmed	TuBG1 promotes hepatocellular carcinoma via ATR/P53-apoptosis and cycling pathways.	ATR TP53	4.06e-06	3	41	2	37806848
Pubmed	XPA-mediated regulation of global nucleotide excision repair by ATR Is p53-dependent and occurs primarily in S-phase.	ATR TP53	4.06e-06	3	41	2	22174788
Pubmed	Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity.	ATR TP53	4.06e-06	3	41	2	25336189
Pubmed	The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues.	RYR1 RYR2	4.06e-06	3	41	2	7876312
Pubmed	Metastatic role of mammalian target of rapamycin signaling activation by chemoradiotherapy in advanced rectal cancer.	MTOR TP53	4.06e-06	3	41	2	31997546
Pubmed	Dendritic differentiation of cerebellar Purkinje cells is promoted by ryanodine receptors expressed by Purkinje and granule cells.	RYR1 RYR2	4.06e-06	3	41	2	24123915
Pubmed	Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.	MTOR TP53	4.06e-06	3	41	2	33378012
Pubmed	The omega-3 polyunsaturated fatty acid DHA induces simultaneous apoptosis and autophagy via mitochondrial ROS-mediated Akt-mTOR signaling in prostate cancer cells expressing mutant p53.	MTOR TP53	4.06e-06	3	41	2	23841076
Pubmed	The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.	MTOR TP53	4.06e-06	3	41	2	18548093
Pubmed	Bidirectional coupling between ryanodine receptors and Ca2+ release-activated Ca2+ (CRAC) channel machinery sustains store-operated Ca2+ entry in human T lymphocytes.	RYR1 RYR2	4.06e-06	3	41	2	22948152
Pubmed	Heightened uterine mammalian target of rapamycin complex 1 (mTORC1) signaling provokes preterm birth in mice.	MTOR TP53	4.06e-06	3	41	2	22025690
Pubmed	Developmental changes in expression of the three ryanodine receptor mRNAs in the mouse brain.	RYR1 RYR2	4.06e-06	3	41	2	10788707
Pubmed	Ca(2+)-induced Ca2+ release in myocytes from dyspedic mice lacking the type-1 ryanodine receptor.	RYR1 RYR2	4.06e-06	3	41	2	7621815
Pubmed	Hyperoxia activates the ATR-Chk1 pathway and phosphorylates p53 at multiple sites.	ATR TP53	4.06e-06	3	41	2	12959929
Pubmed	Molecular identification of the ryanodine receptor pore-forming segment.	RYR1 RYR2	4.06e-06	3	41	2	10473538
Pubmed	Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.	MTOR TP53	4.06e-06	3	41	2	19225536
Pubmed	The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes.	ATR TP53	4.06e-06	3	41	2	14755251
Pubmed	p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.	MTOR TP53	4.06e-06	3	41	2	28821555
Pubmed	TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.	MTOR TP53	4.06e-06	3	41	2	27533080
Pubmed	Expression of the ryanodine receptor type 3 calcium release channel during development and differentiation of mammalian skeletal muscle cells.	RYR1 RYR2	4.06e-06	3	41	2	9242641
Pubmed	Direct association of the reticulon protein RTN1A with the ryanodine receptor 2 in neurons.	RYR1 RYR2	4.06e-06	3	41	2	23454728
Pubmed	A gene-specific cerebral types 1, 2, and 3 RyR protein knockdown induces an antidepressant-like effect in mice.	RYR1 RYR2	4.06e-06	3	41	2	18643873
Pubmed	Intracellular calcium release channel expression during embryogenesis.	RYR1 RYR2	4.06e-06	3	41	2	9986730
Pubmed	Feedback control of p53 translation by REDD1 and mTORC1 limits the p53-dependent DNA damage response.	MTOR TP53	4.06e-06	3	41	2	21896779
Pubmed	The organization of proteins in the human red blood cell membrane. A review.	RYR1 RYR2	4.06e-06	3	41	2	4600883
Pubmed	Prdm12 Directs Nociceptive Sensory Neuron Development by Regulating the Expression of the NGF Receptor TrkA.	EVX1 VSX1 EVX2	8.09e-06	33	41	3	30917309
Pubmed	Met acts on Mdm2 via mTOR to signal cell survival during development.	MTOR TP53	8.12e-06	4	41	2	17329361
Pubmed	Ryanodine receptor calcium release channels: lessons from structure-function studies.	RYR1 RYR2	8.12e-06	4	41	2	23413940
Pubmed	Reconstitution of human claspin-mediated phosphorylation of Chk1 by the ATR (ataxia telangiectasia-mutated and rad3-related) checkpoint kinase.	ATR TP53	8.12e-06	4	41	2	19828454
Pubmed	Nucleophosmin sets a threshold for p53 response to UV radiation.	ATR TP53	8.12e-06	4	41	2	15082766
Pubmed	Partial cloning and differential expression of ryanodine receptor/calcium-release channel genes in human tissues including the hippocampus and cerebellum.	RYR1 RYR2	8.12e-06	4	41	2	9607712
Pubmed	Conserved and divergent functions of Nfix in skeletal muscle development during vertebrate evolution.	RYR1 RYR2	8.12e-06	4	41	2	23482488
Pubmed	A glutathione deficit alters dopamine modulation of L-type calcium channels via D2 and ryanodine receptors in neurons.	RYR1 RYR2	8.12e-06	4	41	2	18206662
Pubmed	TP53-dependent autophagy links the ATR-CHEK1 axis activation to proinflammatory VEGFA production in human bronchial epithelial cells exposed to fine particulate matter (PM2.5).	ATR TP53	8.12e-06	4	41	2	27463284
Pubmed	A positive role for c-Abl in Atm and Atr activation in DNA damage response.	ATR TP53	8.12e-06	4	41	2	20798688
Cytoband	1q44	OR2M5 OR2M3 OR2M7 OR2M2 OR2G6	5.04e-08	110	41	5	1q44
Cytoband	Ensembl 112 genes in cytogenetic band chr1q44	OR2M5 OR2M3 OR2M7 OR2M2 OR2G6	1.08e-07	128	41	5	chr1q44
GeneFamily	Olfactory receptors, family 2	OR2M5 OR2M3 OR2M7 OR2M2 OR2G6	1.80e-06	113	33	5	149
GeneFamily	Ryanodine receptors\|Protein phosphatase 1 regulatory subunits	RYR1 RYR2	9.68e-06	3	33	2	287
GeneFamily	HOXL subclass homeoboxes	EVX1 EVX2	4.05e-03	52	33	2	518
Coexpression	HASLINGER_B_CLL_WITH_17P13_DELETION	EIF4A1 TP53 RYR1	4.25e-06	22	38	3	M3256
ToppCell	COVID-19-Heart-Fib_+_CM\|Heart / Disease (COVID-19 only), tissue and cell type	PFKM VSX1 NEB RYR1	2.55e-06	104	41	4	0b60a56a46f1fe3f8224ec6399d009a34a117a21
ToppCell	COVID-19-Heart-Fib_+_CM\|COVID-19 / Disease (COVID-19 only), tissue and cell type	PFKM VSX1 NEB RYR1	3.43e-06	112	41	4	d00ee6b19e41a35450681fe676885983536d6292
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L2/3_IT-L2/3_IT_VISp_Rrad\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	RRAD C1QL3 RYR1 ADAMTSL2	7.86e-06	138	41	4	b3a040c5d0e1cc94d9b19155bca8700edba2d243
ToppCell	P03-Hematopoietic-Erythroid\|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	GLS2 SLC25A37 RYR1 HCN3	9.29e-06	144	41	4	2ee6a834860eac7ed004f366ab4fc38c4b80c905
ToppCell	P03-Hematopoietic-Erythroid-enucleate_erythrocyte\|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	GLS2 SLC25A37 RYR1 HCN3	9.29e-06	144	41	4	9fa63904389f4d7163db22ea85ab721d8f6e8d99
ToppCell	frontal_cortex-Neuronal-glutamatergic_neuron-L5_IT-L5_IT_ALM_Tnc\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	RRAD NEB C1QL3 ADAMTSL2	1.21e-05	154	41	4	0066b2b8cfc74603e97f271ef5efc7ec512110dc
ToppCell	facs-Brain_Non-Myeloid-Hippocampus_-18m-Macroglial-astrocyte\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LIX1 ABCC8 RYR1 MFAP3L	1.21e-05	154	41	4	5ed64bbf603290e6dc34f81d145982690b89dd0d
ToppCell	Adult-Mesenchymal-vascular_smooth_muscle_cell-D122\|Adult / Lineage, Cell type, age group and donor	RRAD RYR2 GZMK FOXC2	1.41e-05	160	41	4	fd14dfeb7021a4b7299371854dc8fc1fd66c8dae
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_3\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	RRAD RYR2 MFAP3L FOXC2	2.54e-05	186	41	4	4780af76237d7af2abbe2d8d5530cdf53e3ed0b7
ToppCell	wk_08-11-Mesenchymal-Myofibro_&_SMC-Vascular_SMC_1\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	RRAD HIGD1B LIX1 FOXC2	2.59e-05	187	41	4	1aebf6fab40b96f2f5feb77a302bb805838fccf3
ToppCell	wk_08-11-Mesenchymal-Myofibro_&_SMC-Vascular_SMC_2\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	RRAD HIGD1B LIX1 FOXC2	2.59e-05	187	41	4	406ff9327d3109fe1e251629c4c617b00a573dc2
ToppCell	droplet-Heart-4Chambers-21m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRAD PFKM ABCC8 RYR2	2.82e-05	191	41	4	715f5b449b8e075959c05a5b38389df319663164
ToppCell	droplet-Heart-4Chambers-21m-Mesenchymal-cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRAD PFKM ABCC8 RYR2	2.82e-05	191	41	4	c172c9e17b893b290e4aa8af5e5e4cd3e4818372
ToppCell	droplet-Heart-nan-24m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRAD PFKM ABCC8 RYR2	2.88e-05	192	41	4	1a0c25106ae08eac912a4edd5fc1a3ee776f69c2
ToppCell	droplet-Heart-nan-18m-Mesenchymal-cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRAD PFKM ABCC8 RYR2	2.88e-05	192	41	4	0bf99e029a06151092db1e8a0dcb45f4e688e771
ToppCell	droplet-Heart-nan-24m-Mesenchymal-cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRAD PFKM ABCC8 RYR2	2.88e-05	192	41	4	f6a4e348406a852ace9fb21db8fbdff539217645
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_myocytic-mes_pericyte_(14)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	RRAD HIGD1B LIX1 RYR2	2.88e-05	192	41	4	5000440dc1ed17e7474d340921bdff945646f27e
ToppCell	droplet-Heart-nan-18m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRAD PFKM ABCC8 RYR2	2.88e-05	192	41	4	d766221acfce30cbf2c60b3ae40f6744968b952c
ToppCell	wk_15-18-Mesenchymal-Myofibro_&_SMC-Vascular_SMC_2\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	RRAD HIGD1B LIX1 FOXC2	2.94e-05	193	41	4	360079cbaa18b74e4a48c5de40844faca076e1a6
ToppCell	droplet-Heart-HEART-1m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRAD PFKM ABCC8 RYR2	3.12e-05	196	41	4	fba52a4b82086dbae9a55038bf44c4539be926f5
ToppCell	wk_15-18-Mesenchymal-Myofibro_&_SMC-Vascular_SMC_1\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	RRAD HIGD1B LIX1 FOXC2	3.12e-05	196	41	4	40cae477b3906623d1f2a4c630279e710499ce80
ToppCell	droplet-Heart-HEART-1m-Mesenchymal-cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRAD PFKM ABCC8 RYR2	3.12e-05	196	41	4	a582130862bee76c0385156a333bfdfc75cf218b
ToppCell	COVID-19-Heart-Mito_CM\|COVID-19 / Disease (COVID-19 only), tissue and cell type	RRAD PFKM NEB RYR2	3.18e-05	197	41	4	44e49943d62bfe622b40ad0460093d31540544df
ToppCell	distal-mesenchymal-Vascular_Smooth_Muscle-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	RRAD HIGD1B RYR2 FOXC2	3.18e-05	197	41	4	da653dc7d216e202f390e5ab0245f243e3ed213b
ToppCell	distal-2-mesenchymal-Vascular_Smooth_Muscle\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	RRAD HIGD1B RYR2 FOXC2	3.24e-05	198	41	4	ce05ede69c167b2294630709bb0c223483a6ef75
ToppCell	COVID-19-Heart-Mito_CM\|Heart / Disease (COVID-19 only), tissue and cell type	ZNF106 RRAD PFKM NEB	3.24e-05	198	41	4	b6cd439863d17209b86dc50ae51282dc1725955d
ToppCell	TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_and_Papillary_Adenocarcinoma\|TCGA-Pancreas / Sample_Type by Project: Shred V9	OR2M5 OR2M7 OR2M2	6.59e-05	85	41	3	aa4495ffac8daa0aa99b75d03b75af69a675b703
ToppCell	COVID-19-kidney-Epithelial_Doublet\|kidney / Disease (COVID-19 only), tissue and cell type	OR2M7 RYR1 RYR2	2.02e-04	124	41	3	d6f59ddb9b9df02b5201f23fa5fb78f3fd891ee9
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L5_PT-L5_PT_VISp_Chrna6\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	LIX1 C1QL3 ADAMTSL2	2.07e-04	125	41	3	fac8a9bff83abb8976013ff7d2b4ce0b68fbb70a
ToppCell	Bronchial-10x5prime-Hematologic\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	HIGD1B OR2G6 SLC25A37	2.12e-04	126	41	3	b6482ef18e6d9e12ba4810ce7845f9f991cb95bc
ToppCell	Bronchial-10x5prime-Hematologic-Erythrocyte\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	HIGD1B OR2G6 SLC25A37	2.12e-04	126	41	3	65c7c0e4cfb5ac58d80b4034d42e9f662116e0d3
ToppCell	Bronchial-10x5prime-Hematologic-Erythrocyte-Erythrocyte\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	HIGD1B OR2G6 SLC25A37	2.12e-04	126	41	3	12f3d0f60db462f2a9799b3a06005bc871670760
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L5_PT-L5_PT_VISp_C1ql2_Cdh13\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	LIX1 RYR1 ADAMTSL2	2.65e-04	136	41	3	1f3000d5f105c87c80f8ae1dd2264bcd7f757a9c
ToppCell	COVID-19-Heart-CM_5_(RYR2-)\|COVID-19 / Disease (COVID-19 only), tissue and cell type	PFKM NEB RYR1	3.13e-04	144	41	3	f92e03dd784e31a9e5dbd4f4c3a6517ea19210cf
ToppCell	frontal_cortex-Neuronal-glutamatergic_neuron-L2/3_IT\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	C1QL3 RYR1 ADAMTSL2	3.39e-04	148	41	3	d5cace5605bff2bb8248fadb51f2dad7539930ba
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ABCC8 RYR2 FOXC2	3.67e-04	152	41	3	0cb5f4dfae04e3f4eba502bbf229007d5fa3884d
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ABCC8 RYR2 FOXC2	3.67e-04	152	41	3	ba89ffb5a8bb33c188f854f54b39123b6d73496a
ToppCell	COVID-19-Heart-CM_5_(RYR2-)\|Heart / Disease (COVID-19 only), tissue and cell type	PFKM NEB RYR1	3.88e-04	155	41	3	d7e26696fd9c0a759524f331243db43059b33ed9
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Myocytic\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	RRAD HIGD1B RYR2	3.96e-04	156	41	3	6365b69ede98bc866e996bc52736b00401aacf6f
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L2/3_IT-L2/3_IT_VISp_Adamts2\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	C1QL3 RYR1 ADAMTSL2	3.96e-04	156	41	3	2cd007b423c2395c5ce331902e7f27c805755eb3
ToppCell	facs-Heart-RA-24m-Mesenchymal-atrial_myocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLC25A37 ABCC8 RYR2	4.03e-04	157	41	3	9021900d9b1a71210c9c414a9d165eaf399eb607
ToppCell	facs-Heart-RA-24m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLC25A37 ABCC8 RYR2	4.03e-04	157	41	3	c8c627ca181856cd31dba4cf073c2be659a49dc1
ToppCell	Adult-Mesenchymal-vascular_smooth_muscle_cell-D231\|Adult / Lineage, Cell type, age group and donor	RRAD RYR2 FOXC2	4.11e-04	158	41	3	8d64c0c9de910a3f4658778642d183c8b9b6f6a2
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Myeloid-Granulocytic-Neutrophil\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	VSX1 SLC25A37 ABCC8	4.18e-04	159	41	3	6c0ef40f64d2e35eaae3d0002e3c1f22d1239736
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Myeloid-Granulocytic\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	VSX1 SLC25A37 ABCC8	4.18e-04	159	41	3	745a59c33b04620c5329bdd50e74a8e611f2dc55
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L2/3_IT\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	C1QL3 RYR1 ADAMTSL2	4.34e-04	161	41	3	e3327c296d48e821004e61a573abb75624a6f040
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c02-NCAM1\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	VSX1 HIGD1B GZMK	4.50e-04	163	41	3	1c014e373667be290d7fb5d24c06c6f313ac8fa3
ToppCell	facs-Pancreas-Exocrine-18m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PFKM ZMYM4 MFAP3L	4.50e-04	163	41	3	953a7db7e90a913e81002d2141fbbd5f1fdf2197
ToppCell	facs-Heart-LA-24m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EVX1 PFKM RYR2	4.74e-04	166	41	3	c43aec09578975df8984886993d15b42a10190c8
ToppCell	facs-Heart-LA-24m-Mesenchymal-atrial_myocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EVX1 PFKM RYR2	4.74e-04	166	41	3	829a8998ce68739a58202851afd73e049ab0f84f
ToppCell	Substantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Th\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	NEB LIX1 HCN3	4.74e-04	166	41	3	6a6ed5c7a43fee9a8a9be42dfa99303815b8e8ef
ToppCell	Endothelial-B-Donor_04\|World / lung cells shred on cell class, cell subclass, sample id	NEB RYR2 FOXC2	4.83e-04	167	41	3	6a03d16165e0b003092c39972928981abd4a75aa
ToppCell	facs-Marrow-T-cells-3m-Hematologic-MPP_Fraction_B_+_C\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GLS2 ATR G6PC1	5.08e-04	170	41	3	d70aaa0f4e5034bb9f61b832b5f9123870936d3c
ToppCell	Control-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_3\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	RRAD RYR2 FOXC2	5.17e-04	171	41	3	4ede831aed364cb5271f49a8b09bb6d0452f9b35
ToppCell	COVID-19-Heart-T_cell\|COVID-19 / Disease (COVID-19 only), tissue and cell type	NEB LIX1 RYR1	5.17e-04	171	41	3	b2e753e811a7639956994609f73efcdb62d04f82
ToppCell	Healthy_donor-MAIT\|World / disease group, cell group and cell class (v2)	PLPP2 ADAMTSL2 GZMK	5.26e-04	172	41	3	6524eb2be1c78700ad367e62624a4d7eb48b54f0
ToppCell	Adult-Mesenchymal-vascular_smooth_muscle_cell\|Adult / Lineage, Cell type, age group and donor	RRAD RYR2 FOXC2	5.26e-04	172	41	3	c62cad0f4212d1e9ea1ec3143ad3c4e06aff0ebf
ToppCell	facs-Heart-Unknown-3m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NEB ABCC8 RYR2	5.26e-04	172	41	3	bd468a7ea6ec832dcf6a816a1e0c03fa0f176dad
ToppCell	facs-Heart-Unknown-3m-Mesenchymal-atrial_myocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NEB ABCC8 RYR2	5.26e-04	172	41	3	ee8ce9e8c9a6d3ee2be113f77743958005f4b3f0
ToppCell	Children_(3_yrs)-Mesenchymal-vascular_smooth_muscle_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	RRAD RYR2 FOXC2	5.35e-04	173	41	3	5416b092321c7d9b63f0418c60f2402a138355bf
ToppCell	facs-Lung-24m-Mesenchymal-myofibroblast\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	RRAD HIGD1B MFAP3L	5.44e-04	174	41	3	a7ade7372e83edd4e3983e77f8417b51f0b47340
ToppCell	droplet-Heart-nan-3m\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZNF106 RYR2 ADAMTSL2	5.62e-04	176	41	3	749b47eac5436fa34e0d243ffbc6f1897f4e431e
ToppCell	Children_(3_yrs)-Mesenchymal-pericyte_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	RRAD HIGD1B RYR2	5.81e-04	178	41	3	185b44700f06ec58b3c09c80520502166c965fd6
ToppCell	Fetal_29-31_weeks-Mesenchymal-vascular_smooth_muscle_cell-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	RRAD ABCC8 FOXC2	5.81e-04	178	41	3	066dbc4cc2083c549d98122ed44707127f34d582
ToppCell	facs-Thymus-Thymus_Flowthrough-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TMBIM6 EIF4A1 GZMK	6.00e-04	180	41	3	de87503d9caac3ebc80ab8090c1a9ee5a925b2a0
ToppCell	droplet-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l6-17\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	GLS2 HIGD1B ADAMTSL2	6.00e-04	180	41	3	455d1e3ccf2ab609954f3b870e8f514ddca735f4
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Mesenchymal-Pericytes-Contractile_pericyte_(PLN+)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	RRAD HIGD1B ABCC8	6.00e-04	180	41	3	4fb95ed39508bede5472dd36aeabe91b33631726
ToppCell	5'-GW_trimst-2-LymphNode-Mesenchymal-Pericytes-Contractile_pericyte_(PLN+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	RRAD HIGD1B FOXC2	6.10e-04	181	41	3	59527ad218e49386b04cabb97d53d2ed55a35961
ToppCell	droplet-Heart-4Chambers-18m-Mesenchymal-cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PFKM ABCC8 RYR2	6.10e-04	181	41	3	09a574a3257e25c8b05a2ab20623a6b07331411a
ToppCell	Children_(3_yrs)-Mesenchymal-pericyte_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	RRAD HIGD1B RYR2	6.10e-04	181	41	3	451b87ac95154bb80018b8dd245b4a6389d81411
ToppCell	droplet-Heart-4Chambers-18m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PFKM ABCC8 RYR2	6.10e-04	181	41	3	ac4142aa93706b7067f63d2d38e2456859e60768
ToppCell	Healthy_donor-MAIT\|Healthy_donor / disease group, cell group and cell class (v2)	PLPP2 ADAMTSL2 GZMK	6.20e-04	182	41	3	ac7c83464487ecde3df6804a99551307bd768f21
ToppCell	lymphoid-T_cell-CD8+_Effector_T_cell\|lymphoid / Lineage, cell class and subclass	PLPP2 RYR1 GZMK	6.20e-04	182	41	3	d4ef4a7c0f5dc044eb5cc6c0bcf539c88b1b4fef
ToppCell	Globus_pallidus-Neuronal-Inhibitory\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	GLS2 ABCC8 HCN3	6.20e-04	182	41	3	04ccfa951eaa31fed6d140edb6c702d49363c5fa
ToppCell	facs-Heart-LA-3m-Mesenchymal-atrial_myocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRAD PFKM RYR2	6.30e-04	183	41	3	905e1e9be0f15be184447df04b134a6aa8279074
ToppCell	facs-Heart-LA-3m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRAD PFKM RYR2	6.30e-04	183	41	3	92eed783347a372b850de3189e72525082390014
ToppCell	droplet-Limb_Muscle-nan-21m-Mesenchymal-unknown\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PFKM NEB HIGD1B	6.30e-04	183	41	3	6f5dbac2748f50105f0f548d189c42ef14287019
ToppCell	facs-Lung-EPCAM-24m-Mesenchymal-Pericyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRAD HIGD1B MFAP3L	6.30e-04	183	41	3	0e8fb371d8eac777451c76f41d53577f5dfb740d
ToppCell	Adult-Mesenchymal-pericyte_cell-D122\|Adult / Lineage, Cell type, age group and donor	RRAD HIGD1B RYR2	6.30e-04	183	41	3	fc31a43a637423cb3bb9aa184a3a889a0b9aaea6
ToppCell	facs-Lung-EPCAM-24m-Mesenchymal-pericyte_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRAD HIGD1B MFAP3L	6.30e-04	183	41	3	cbc3b00faa7e4e0dbbbc8ee105467c65241c7470
ToppCell	lymphoid-T_cell-CD8+_Effector_T_cell\|T_cell / Lineage, cell class and subclass	PLPP2 RYR1 GZMK	6.40e-04	184	41	3	f610f28f8319d194871a3e94210bf1c493918986
ToppCell	facs-Lung-24m-Mesenchymal-myofibroblast-pericyte_cell-pericyte\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	RRAD HIGD1B MFAP3L	6.50e-04	185	41	3	a6cd90f8f30c7bdf66958cf403e73c193aa32f5e
ToppCell	facs-Lung-24m-Mesenchymal-myofibroblast-pericyte_cell\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	RRAD HIGD1B MFAP3L	6.50e-04	185	41	3	5053f932e2adfcf4d6faaecff2999ac53d8d7aa5
ToppCell	facs-Bladder-nan-18m\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TMBIM6 EIF4A1 RYR2	6.50e-04	185	41	3	3e00879466e626aa8604efecfc4678d64f54dbfc
ToppCell	facs-Bladder-nan-18m-Epithelial\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TMBIM6 EIF4A1 RYR2	6.50e-04	185	41	3	3dc5812c961ff209f197ff4cbfb90009c0537550
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_3\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	RRAD RYR2 FOXC2	6.60e-04	186	41	3	a95744b8649096bd7cfc3591a02841fa411085b3
ToppCell	3'-GW_trimst-1-LargeIntestine-Mesenchymal-Pericytes-Contractile_pericyte_(PLN+)\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	RRAD HIGD1B FOXC2	6.71e-04	187	41	3	d52f7bc0afcdc366b20d199ab33c4ec60ed22a68
ToppCell	Children_(3_yrs)-Mesenchymal-pericyte_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	RRAD HIGD1B RYR2	6.71e-04	187	41	3	86250acf088ec0c4800a0dfa031b0d4f7e52c342
ToppCell	Adult-Mesenchymal-pericyte_cell\|Adult / Lineage, Cell type, age group and donor	RRAD HIGD1B RYR2	6.71e-04	187	41	3	62759efb660179402fb574ce5701c89a2e17bcfe
ToppCell	E17.5-Mesenchymal-myocytic_cell-vascular_associated_smooth_muscle_cell\|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	RRAD HIGD1B FOXC2	6.71e-04	187	41	3	0dee138738b65531ff134a125b92234b5d0a653c
ToppCell	Fetal_29-31_weeks-Mesenchymal-pericyte_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	RRAD HIGD1B RYR2	6.71e-04	187	41	3	a2bf958ea59c359a265bfa437d59315e1920cdd4
ToppCell	15-Distal-Mesenchymal-Pericyte\|Distal / Age, Tissue, Lineage and Cell class	RRAD HIGD1B LIX1	6.81e-04	188	41	3	4963382e54aac06bf5047c7d725393db70667ee7
ToppCell	HSPCs-Ery/Mk_prog.\|World / Lineage and Cell class	RRAD EIF4A1 TP53	6.81e-04	188	41	3	5390089213cd6ee90dcdfd3c3f5b6765376cccf2
ToppCell	11.5-Airway-Mesenchymal-Pericyte\|Airway / Age, Tissue, Lineage and Cell class	RRAD HIGD1B LIX1	6.81e-04	188	41	3	916971d8660fd20f616346953874e89d2cd13e88
ToppCell	Children_(3_yrs)-Mesenchymal-pericyte_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	RRAD HIGD1B RYR2	6.81e-04	188	41	3	ee151792c7ac9afe820f1a281c6dab383799f358
ToppCell	facs-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l39\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	RRAD HIGD1B RYR2	6.81e-04	188	41	3	a5e7a363fbd5ae4d9312cf6f9941413d6a5c0b4d
ToppCell	Fetal_29-31_weeks-Mesenchymal-pericyte_cell-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	RRAD HIGD1B ADAMTSL2	6.81e-04	188	41	3	ccddc08121caff958a2b6f9e278a018858af6b4d
ToppCell	facs-MAT-Fat-18m\|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TMBIM6 EIF4A1 GZMK	6.81e-04	188	41	3	7f0cda7aab442aa9511d4c35569ec2389e014a71
ToppCell	5'-GW_trimst-2-LargeIntestine-Mesenchymal-Pericytes-Contractile_pericyte_(PLN+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	RRAD HIGD1B FOXC2	6.81e-04	188	41	3	c2321a3a1d9603f8b4b4fc09707eb32ec1e04f3f
ToppCell	Striatum-Endothelial\|Striatum / BrainAtlas - Mouse McCarroll V32	RRAD HIGD1B FOXC2	6.92e-04	189	41	3	95ee3b6d7fbbfcf91c780dfcd0926acec05f0a2d
Drug	Big Chap	RRAD TP53	8.57e-06	3	39	2	CID003828172
Drug	methylophiopogonanone B	SGMS1 TP53	8.57e-06	3	39	2	CID005319742
Drug	2-hydroxycarbazole	RYR1 RYR2	8.57e-06	3	39	2	CID000093551
Drug	cis-diammineplatinum(II	RYR1 RYR2	8.57e-06	3	39	2	CID000159790
Drug	2-hydroxyheptanoic acid	RYR1 RYR2	8.57e-06	3	39	2	CID002750949
Drug	Ryanodyl 3-(pyridine-3-carboxylate	RYR1 RYR2	8.57e-06	3	39	2	CID005748312
Drug	8N3-cADPR	RYR1 RYR2	8.57e-06	3	39	2	CID000127713
Drug	aminodantrolene	RYR1 RYR2	8.57e-06	3	39	2	CID009570289
Drug	Flavanones	ATR MTOR TP53	9.17e-06	24	39	3	ctd:D044950
Drug	PCB74	RYR1 RYR2	1.71e-05	4	39	2	CID000036218
Drug	148504-47-6	RYR1 RYR2	1.71e-05	4	39	2	CID006444275
Drug	SC 38249	RYR1 RYR2	1.71e-05	4	39	2	CID000134834
Drug	AC1L1U7A	RYR1 RYR2	1.71e-05	4	39	2	CID000035682
Drug	M3/M4	MTOR RYR1 RYR2	2.23e-05	32	39	3	CID000486507
Drug	Caffeine	PFKM ATR MTOR SLC25A37 TP53 RYR1 RYR2	2.39e-05	515	39	7	ctd:D002110
Drug	NSC 724998	ATR TP53	2.85e-05	5	39	2	ctd:C553898
Drug	A 68930	RYR1 RYR2	2.85e-05	5	39	2	ctd:C065380
Drug	4-chloro-m-cresol	RRAD RYR1 RYR2	3.47e-05	37	39	3	CID000001732
Drug	NAADP	MTOR RYR1 RYR2	4.07e-05	39	39	3	CID000123952
Drug	MBED	RYR1 RYR2	4.27e-05	6	39	2	CID000129958
Drug	chloro-m-cresol	RYR1 RYR2	4.27e-05	6	39	2	CID000012008
Drug	AC1O528X	RYR1 RYR2	4.27e-05	6	39	2	CID006475857
Drug	NSC114784	RYR1 RYR2	4.27e-05	6	39	2	CID000419425
Drug	OPC-14117	MTOR TP53	4.27e-05	6	39	2	CID000059739
Drug	NSC226080	PSMD1 PFKM G6PC1 MTOR EIF4A1 TP53 RYR1 RYR2	4.47e-05	782	39	8	CID000005040
Drug	Azumoleno	RYR1 RYR2	5.97e-05	7	39	2	CID000056259
Drug	Br2BAPTA	RYR1 RYR2	5.97e-05	7	39	2	CID003081001
Drug	[[(2R,3S,4R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate	RYR1 RYR2	5.97e-05	7	39	2	CID009547999
Drug	Ecdysterone	MTOR TP53	7.95e-05	8	39	2	ctd:D004441
Drug	butanol	PLPP2 G6PC1 MTOR TP53	1.01e-04	142	39	4	CID000000263
Drug	(19Z)-halichondramide	MTOR TP53	1.02e-04	9	39	2	ctd:C495172
Drug	AC1L494B	PFKM G6PC1 ABCC8	1.03e-04	53	39	3	CID000181487
Drug	manganese tetrakis-(N-ethyl-2 pyridyl) porphyrin	MTOR TP53	1.28e-04	10	39	2	ctd:C520506
Drug	thio-dimethylarsinate	ATR TP53	1.28e-04	10	39	2	ctd:C523062
Drug	PCB 95	RYR1 RYR2	1.28e-04	10	39	2	CID000038012
Drug	4-methyldaphnetin	MTOR TP53	1.28e-04	10	39	2	CID005355836
Drug	sodium arsenite	COX10 ZNF106 G6PC1 TP53	1.31e-04	152	39	4	CID000443495
Drug	isocitrate	PFKM G6PC1 RYR1 RYR2	1.45e-04	156	39	4	CID000001198
Drug	1,1,1-trichloroethane	RRAD ATR MTOR TP53	1.45e-04	156	39	4	CID000006278
Drug	2,3,6,2',3',6'-hexachlorobiphenyl	RYR1 RYR2	1.56e-04	11	39	2	ctd:C010498
Drug	PCB 66	RYR1 RYR2	1.56e-04	11	39	2	CID000036185
Drug	R 478	RYR1 RYR2	1.56e-04	11	39	2	CID000084223
Drug	8-amino-cADPR	RYR1 RYR2	1.56e-04	11	39	2	CID003081323
Drug	tectoridin	RYR1 RYR2	1.56e-04	11	39	2	CID005281810
Drug	AICAR monophosphate	PFKM G6PC1 MTOR TP53	1.71e-04	163	39	4	CID000000200
Drug	perifosine	SGMS1 MTOR TP53	1.80e-04	64	39	3	CID000148177
Drug	Ryanodine	RYR1 RYR2	1.87e-04	12	39	2	ctd:D012433
Drug	adenine	PFKM MTOR ABCC8 TP53 RYR1 RYR2	2.14e-04	510	39	6	CID000000190
Drug	NSC299933	TMBIM6 RYR1	2.20e-04	13	39	2	CID000431902
Drug	DALM	MTOR TP53	2.20e-04	13	39	2	CID000164233
Drug	AC1L1UJE	SGMS1 ABCC8	2.20e-04	13	39	2	CID000010121
Drug	AC1L1D8L	MTOR RYR1 RYR2	2.45e-04	71	39	3	CID000002241
Drug	quinolinic acid	PSMD1 PFKM MTOR TP53	2.45e-04	179	39	4	CID000001066
Drug	sebacate	SPO11 ATR MTOR TP53	2.56e-04	181	39	4	CID000005192
Drug	avenaciolide	PFKM G6PC1	2.57e-04	14	39	2	CID000089293
Drug	FPL 64176	RYR1 RYR2	2.96e-04	15	39	2	CID000003423
Drug	Gvapspat amide	RYR1 RYR2	2.96e-04	15	39	2	CID000125015
Drug	AC1L2A54	PFKM SGMS1 MTOR TP53	3.14e-04	191	39	4	CID000068636
Drug	Adenosine Triphosphate	PFKM ABCC8 TP53 RYR2	3.26e-04	193	39	4	ctd:D000255
Drug	glycerol;phosphate	PFKM PLPP2 G6PC1	3.36e-04	79	39	3	CID000082875
Drug	Floxuridine	ATR TP53	3.38e-04	16	39	2	ctd:D005467
Drug	L 739749	MTOR TP53	3.38e-04	16	39	2	CID000158357
Drug	methyl caffeate	MTOR TP53	3.38e-04	16	39	2	ctd:C042405
Drug	Apomorphine hydrochloride hemihydrate [41372-20-7]; Up 200; 6.4uM; MCF7; HT_HG-U133A	GLS2 MTOR RYR2 MFAP3L	3.46e-04	196	39	4	1505_UP
Drug	Verapamyl hydrochloride [152-11-4]; Down 200; 8.2uM; MCF7; HT_HG-U133A	GLS2 NEB RYR2 MFAP3L	3.53e-04	197	39	4	5387_DN
Drug	prostaglandin E2; Up 200; 10uM; MCF7; HT_HG-U133A	GLS2 NEB SLC25A37 MFAP3L	3.60e-04	198	39	4	6590_UP
Drug	0175029-0000 [211245-78-2]; Up 200; 10uM; PC3; HT_HG-U133A	SPO11 RYR1 MFAP3L GZMK	3.60e-04	198	39	4	3691_UP
Drug	Acrylamide	ATR TP53 RYR1 GZMK	3.67e-04	199	39	4	ctd:D020106
Drug	Aceclofenac [89796-99-6]; Up 200; 11.2uM; MCF7; HT_HG-U133A	GLS2 NEB SLC25A37 RYR2	3.67e-04	199	39	4	7029_UP
Drug	Aphidicolin	ATR TP53	3.83e-04	17	39	2	ctd:D016590
Drug	kazinol B	RYR1 RYR2	3.83e-04	17	39	2	CID000480869
Drug	FTI-276	MTOR TP53	3.83e-04	17	39	2	CID000395753
Drug	N-bromoacetylethanolamine phosphate	PFKM G6PC1	3.83e-04	17	39	2	CID000188343
Drug	radicicol	RRAD PFKM MTOR TP53	3.95e-04	203	39	4	CID000005033
Drug	C13932	PFKM MTOR RYR1 RYR2	4.18e-04	206	39	4	CID000168297
Drug	geldanamicin	RRAD GLS2 PFKM MTOR TP53	4.18e-04	373	39	5	CID000003460
Drug	schizandrin B	ATR TP53	4.30e-04	18	39	2	ctd:C015499
Drug	methylcoumarin	RYR1 RYR2	4.30e-04	18	39	2	CID000007092
Drug	fosbretabulin	G6PC1 MTOR	4.30e-04	18	39	2	ctd:C058728
Drug	3-[18-(2-carboxyethyl)-8-(1-hydroxy-5,9,13-trimethyl-tetradeca-4,8,12-trienyl)-3,7,12,17-tetramethyl-13-vinyl-1,2,3,6,7,8,9,12,17,18-decahydroporphine-21,22,23,24-tetraid-2-yl]propionic acid;iron(4+)	COX10 RYR1	4.30e-04	18	39	2	CID011984599
Drug	bromopyruvate	MTOR TP53	4.30e-04	18	39	2	ctd:C017092
Drug	NSC-85998	PFKM G6PC1	4.30e-04	18	39	2	CID000005299
Drug	Isocyanates	ATR TP53	4.30e-04	18	39	2	ctd:D017953
Drug	DB07328	PFKM G6PC1 MTOR TP53	4.33e-04	208	39	4	CID011840913
Drug	AMPK inhibitor	G6PC1 MTOR TP53	4.77e-04	89	39	3	CID011524144
Drug	Akti-1/2	G6PC1 MTOR	4.80e-04	19	39	2	CID010196499
Drug	ferroheme-O	COX10 RYR1	4.80e-04	19	39	2	CID004369157
Drug	AC1L380G	RYR1 RYR2	4.80e-04	19	39	2	CID000084698
Drug	AC1MW7VF	RYR1 RYR2	4.80e-04	19	39	2	CID000414699
Drug	SK&F 82958	RYR1 RYR2	4.80e-04	19	39	2	ctd:C071262
Drug	Daunorubicin	PFKM MTOR TP53 RYR2	4.99e-04	216	39	4	ctd:D003630
Drug	Baclofen	RYR1 RYR2	5.33e-04	20	39	2	ctd:D001418
Drug	2,2',3,5',6-pentachlorobiphenyl	RYR1 RYR2	5.33e-04	20	39	2	ctd:C032904
Drug	benzo(a)pyrene-7,8-dione	TP53 RYR1	5.33e-04	20	39	2	CID000105020
Drug	ruthenium	TP53 RYR1 RYR2	5.59e-04	94	39	3	CID000023950
Drug	1n9a	RRAD MTOR TP53	5.77e-04	95	39	3	CID004631604
Drug	AC1L1HFP	SPO11 ATR MTOR	5.77e-04	95	39	3	CID000004111
Drug	indo-1/AM	RYR1 RYR2	5.88e-04	21	39	2	CID000123918
Drug	AC1NQZNV	PFKM G6PC1	5.88e-04	21	39	2	CID005282208
Drug	34 C	TP53 RYR1	5.88e-04	21	39	2	CID000002084
Disease	congenital myopathy 1A (implicated_via_orthology)	RYR1 RYR2	5.10e-06	3	39	2	DOID:3529 (implicated_via_orthology)
Disease	malignant hyperthermia (implicated_via_orthology)	RYR1 RYR2	5.10e-06	3	39	2	DOID:8545 (implicated_via_orthology)
Disease	MULTIPLE PTERYGIUM SYNDROME, LETHAL TYPE	NEB RYR1	2.54e-05	6	39	2	C1854678
Disease	Urologic Neoplasms	ATR TP53	4.74e-05	8	39	2	C0042076
Disease	endometrial cancer (implicated_via_orthology)	ATR TP53	4.74e-05	8	39	2	DOID:1380 (implicated_via_orthology)
Disease	Cancer of Urinary Tract	ATR TP53	4.74e-05	8	39	2	C0751571
Disease	Carcinoma, Small Cell	MTOR TP53	6.09e-05	9	39	2	C0262584
Disease	type 2 diabetes mellitus (is_implicated_in)	RRAD MTOR ABCC8 FOXC2	7.64e-05	171	39	4	DOID:9352 (is_implicated_in)
Disease	Congenital myopathy (disorder)	NEB RYR1	1.11e-04	12	39	2	C0270960
Disease	vascular dementia (biomarker_via_orthology)	MTOR TP53	1.53e-04	14	39	2	DOID:8725 (biomarker_via_orthology)
Disease	congestive heart failure (is_marker_for)	RRAD MTOR FOXC2	1.76e-04	82	39	3	DOID:6000 (is_marker_for)
Disease	Glycogen storage disease	PFKM G6PC1	2.29e-04	17	39	2	cv:C0017919
Disease	cervical squamous cell carcinoma (is_marker_for)	TMBIM6 TP53	3.87e-04	22	39	2	DOID:3744 (is_marker_for)
Disease	breast cancer (implicated_via_orthology)	ATR TP53	5.01e-04	25	39	2	DOID:1612 (implicated_via_orthology)
Disease	Glycogen Storage Disease	PFKM G6PC1	5.85e-04	27	39	2	C0017919
Disease	Papillary Renal Cell Carcinoma	MTOR TP53 RYR1	6.50e-04	128	39	3	C1306837
Disease	Malignant Neoplasms	ATR MTOR TP53	6.50e-04	128	39	3	C0006826
Disease	Renal Cell Carcinoma	MTOR TP53 RYR1	6.50e-04	128	39	3	C0007134
Disease	Sarcomatoid Renal Cell Carcinoma	MTOR TP53 RYR1	6.50e-04	128	39	3	C1266043
Disease	Chromophobe Renal Cell Carcinoma	MTOR TP53 RYR1	6.50e-04	128	39	3	C1266042
Disease	Collecting Duct Carcinoma of the Kidney	MTOR TP53 RYR1	6.50e-04	128	39	3	C1266044
Disease	Neoplasm of uncertain or unknown behavior of ovary	ATR TP53	6.76e-04	29	39	2	C0496920
Disease	Ovarian Carcinoma	ATR TP53	7.23e-04	30	39	2	C0029925
Disease	ovarian neoplasm	ATR MTOR TP53	7.43e-04	134	39	3	C0919267
Disease	Malignant neoplasm of ovary	ATR MTOR TP53	7.92e-04	137	39	3	C1140680
Disease	Large cell carcinoma of lung	ATR MTOR	8.23e-04	32	39	2	C0345958
Disease	ascending aortic diameter	SLC25A37 ABCC8 RYR2	8.43e-04	140	39	3	EFO_0021787
Disease	Uterine Cervical Neoplasm	MTOR TP53	9.85e-04	35	39	2	C0007873
Disease	Conventional (Clear Cell) Renal Cell Carcinoma	MTOR TP53 RYR1	9.90e-04	148	39	3	C0279702
Disease	Non-Small Cell Lung Carcinoma	RRAD MTOR TP53	1.15e-03	156	39	3	C0007131

Protein segments in the cluster

Peptide	Gene	Start	Entry
AGTSAHYEMLGTCRM	C1QL3	16	Q5VWW1
YTYMMSHAAAAGGLP	EVX1	256	P49640
YTYMMTHAAATGSLP	EVX2	261	Q03828
AYMTHVCFNMEIIGG	GZMK	16	P49863
DYSRGGYCMMSVTHP	COX10	336	Q12887
GHCMAMGDAYVIVYS	RRAD	156	P55042
SGDMGVYYMVVCLVA	MFAP3L	146	O75121
CAVGAIMLGAVYTMY	HIGD1B	71	Q9P298
TAYGYMRGFMTAHGQ	LSG1	511	Q9H089
MALGDYMGASCHACI	EIF4A1	121	P60842
CSSHLMVVGMYYGAA	OR2M2	241	Q96R28
CSSHLLVVGMYYGAA	OR2M3	241	Q8NG83
CSSHLMVVGMYYGAG	OR2M5	241	A3KFT3
CSSHLMVVGMYYGAG	OR2M7	241	Q8NG81
GCYSQMFFMHLLGGS	OR4K13	96	Q8NH42
ETMGGYCGYLATMAG	PFKM	571	P08237
TTGVMSAYAMCVRYD	ADAMTSL2	581	Q86TH1
SLMHSCGMYDFSGQF	GLS2	391	Q9UI32
AGGYQCSMRAMSLYT	FOXC2	326	Q99958
TIHYNYMCNSSCMGG	TP53	231	P04637
SGHSSFGMYCMVFLA	PLPP2	166	O43688
SMIVGATCYAMFIGH	HCN3	331	Q9P1Z3
SVGAYHYMLESNMGK	LIX1	141	Q8N485
AYCRSTAVMSMVGYI	ATR	2456	Q13535
PSGHAMGTAGVYYVM	G6PC1	116	P35575
LCMFVAAAGAYVHMV	TMBIM6	36	P55061
YHGCYGDIMTMKTSG	LYG2	36	Q86SG7
MTCYLFHMYVGVRAG	RYR1	4881	P21817
TCYMFHMYVGVRAGG	RYR2	4811	Q92736
YAAICHPLHYSSMMS	OR13A1	141	Q8NGR1
TMSYGGCVAQLYVAM	OR2G6	91	Q5TZ20
ESYSRAYGAMVSCHM	MTOR	1581	P42345
IMGAGPAHAMYFACY	SLC25A37	111	Q9NYZ2
SGMYTVAMAYCGSGN	PSMD1	581	Q99460
GMAFMAAVTSVVYYH	ABCC8	111	Q09428
VMAEYGLYGAMVRHC	VSX1	231	Q9NZR4
HGIEIMCIYKYGSMS	SPO11	281	Q9Y5K1
MCGDYLYSGHTVMLT	SGMS1	276	Q86VZ5
MTIHKSMIYTGCYDG	ZNF106	1786	Q9H2Y7
QGCSVSGMTLKYMYG	ZMYM4	1196	Q5VZL5
YVGSMEDPYHTHCMK	NEB	681	P20929